001     298928
005     20250217163750.0
024 7 _ |a 10.1093/jleuko/qiae250
|2 doi
024 7 _ |a pmid:39953806
|2 pmid
024 7 _ |a 0741-5400
|2 ISSN
024 7 _ |a 1938-3673
|2 ISSN
037 _ _ |a DKFZ-2025-00362
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Cibir, Zülal
|b 0
245 _ _ |a Risk beyond neutropenia: insights into neutrophil migration from newly diagnosed AML until late after allogeneic stem cell transplantation.
260 _ _ |a Tokyo
|c 2025
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739788801_14462
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Quantification of neutrophil counts is the most relevant assessment of cellular immunity in clinical practice. Patients with neutropenia are considered at risk and are categorized according to its severity. The incidence of febrile neutropenia varies, but patients with acute myeloid leukemia are traditionally considered at high risk, especially following myelotoxic treatments. To provide additional functional parameters, we investigated the ex vivo migration properties and morphology of neutrophils in 10 patients with acute myeloid leukemia using single-cell video-microscopy and discovered, in addition to neutropenia, highly pathological neutrophil migration patterns and polarization defects in patients with untreated acute myeloid leukemia. Neutrophil speed was the most sensitive parameter and significantly lower at leukemia diagnosis (9.067 vs 15.810 µm/min, P = 0.0025) compared to healthy controls (n = 46). Hematological remission was associated with improved neutrophil migration profiles, but these ultimately normalized only after hematopoietic cell transplantation. Five patients were followed up for long-term effects of hematopoietic cell transplantation for up to 24 mo. This is the first longitudinal ex vivo neutrophil migration study in patients with acute myeloid leukemia, followed by allogeneic hematopoietic cell transplantation. It identified functional neutrophil impairments beyond routine quantitative assessments, adding to the well-known quantitative impairment of neutropenia. HCT can reestablish functional neutrophils with healthy migration profiles in these patients.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a acute myeloid leukemia
|2 Other
650 _ 7 |a myeloid neoplasia
|2 Other
650 _ 7 |a neutrophil granulocytes
|2 Other
650 _ 7 |a transplantation
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: therapy
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: immunology
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: pathology
|2 MeSH
650 _ 2 |a Neutrophils: immunology
|2 MeSH
650 _ 2 |a Neutrophils: pathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neutropenia: etiology
|2 MeSH
650 _ 2 |a Neutropenia: pathology
|2 MeSH
650 _ 2 |a Neutropenia: immunology
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Hematopoietic Stem Cell Transplantation: adverse effects
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Transplantation, Homologous: adverse effects
|2 MeSH
650 _ 2 |a Cell Movement
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Beer, Alexander
|b 1
700 1 _ |a Kraus, Andreas
|b 2
700 1 _ |a Pillibeit, Aleksandra
|b 3
700 1 _ |a Bludau, Dana
|b 4
700 1 _ |a Abdulla, Haji
|b 5
700 1 _ |a Neuendorff, Nina Rosa
|b 6
700 1 _ |a Sonneck, Justin
|b 7
700 1 _ |a Kowitz, Lennart
|b 8
700 1 _ |a Riese, Stefanie
|b 9
700 1 _ |a Tuz, Ali Ata
|b 10
700 1 _ |a Chen, Jianxu
|b 11
700 1 _ |a Cherneha, Maxim
|b 12
700 1 _ |a Beelen, Dietrich W
|b 13
700 1 _ |a Reinhardt, H Christian
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Gunzer, Matthias
|0 0000-0002-5534-6055
|b 15
700 1 _ |a Turki, Amin T
|0 0000-0003-1347-3360
|b 16
773 _ _ |a 10.1093/jleuko/qiae250
|g Vol. 117, no. 2, p. qiae250
|0 PERI:(DE-600)2026833-6
|n 2
|p qiae250
|t Journal of leukocyte biology
|v 117
|y 2025
|x 0741-5400
909 C O |o oai:inrepo02.dkfz.de:298928
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 0000-0003-1347-3360
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-12
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J LEUKOCYTE BIOL : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J LEUKOCYTE BIOL : 2022
|d 2024-12-12
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21